Our data suggest that it deserves to be tested in the two distinct AA mouse models employed here whether blocking OX40L/OX40 (e.g using oxelumab, which was first developed for the treatment of asthma [84], [127]) or 4-1BB/4-1BBL interactions [96], [128], or antagonizing PAR-2 [129], [130] affects the development of AA lesions and/or hair regrowth. The gene discussed is TNFSF4; the disease is asthma.